As the choice of medication for diabetes grows ever wider, non-glycaemic advantages and disadvantages of therapy assume an ever-increasing importance in clinical decision-making. The influence of the money markets, and the roles and responsibilities of physicians and regulators are discussed in this month's Editorial: 'Collateral damage: the conundrum of drug safety' (Diabetologia 52:1975-1982).
Download the high resolution cover image
Cover credit: JAMES KING-HOLMES/SCIENCE PHOTO LIBRARY